Form 4: Zymeworks CEO Reports Future RSU Vesting and Tax Sales

Zymeworks Inc. Chair & CEO Kenneth Galbraith reported pre-scheduled vesting of restricted stock units and subsequent tax-related stock sales set for January 5, 2026.

Summary

• Kenneth Galbraith, Chair & CEO of Zymeworks Inc., reported pre-scheduled transactions related to his beneficial ownership under a Rule 10b5-1 plan.
• On January 5, 2026, 47,668 shares of common stock are scheduled to be acquired upon the vesting of Restricted Stock Units (RSUs) granted on January 5, 2023.
• Concurrently, 22,657 shares are scheduled to be disposed of at a weighted average price of $25.0969 to cover tax withholding obligations from this RSU vesting.
• Also on January 5, 2026, 66,666 shares of common stock are scheduled to be acquired upon the vesting of RSUs granted on January 5, 2024.
• An additional 31,686 shares are scheduled to be disposed of at a weighted average price of $25.0969 to cover tax withholding obligations from this RSU vesting.
• These dispositions are mandatory "sell to cover" transactions pursuant to the RSU grant agreements and do not represent discretionary sales.
• Following these scheduled transactions, Galbraith's direct beneficial ownership of common stock will be 193,266 shares, and 66,668 derivative securities (RSUs) will be beneficially owned.

Sentiment

Score: 5

Explanation: This is a routine, pre-scheduled insider transaction (RSU vesting and tax-related sales) reported under a Rule 10b5-1 plan. It does not reflect discretionary buying or selling by the executive, thus having a neutral impact on sentiment.

Positives

• Kenneth Galbraith, Chair & CEO, is scheduled to receive a significant number of shares (114,334 total) through the vesting of Restricted Stock Units (RSUs), representing a realization of executive compensation.

Negatives

• A total of 54,343 shares are scheduled to be sold by the CEO to cover tax withholding obligations, which, while not discretionary, will increase the public float of shares.

Future Outlook

The filing details pre-scheduled vesting of Restricted Stock Units (RSUs) and associated tax-related stock sales for Kenneth Galbraith on January 5, 2026. These transactions are part of a Rule 10b5-1 plan, indicating they are pre-arranged and not discretionary. The RSUs granted on January 5, 2023, and January 5, 2024, are set to vest in three equal annual installments.

Industry Context

This Form 4 filing is specific to an insider's pre-scheduled equity transactions and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: A minor, pre-scheduled increase in the public float of shares due to tax-related sales, but the transactions are routine and non-discretionary, indicating no change in management's confidence.
• Employees (specifically Kenneth Galbraith): Represents a scheduled realization of compensation through RSU vesting.

Key Dates

Recommendation

The filing details routine, pre-scheduled RSU vesting and mandatory tax-related stock sales by the CEO under a Rule 10b5-1 plan. These are not discretionary transactions and therefore do not signal a change in management's confidence or outlook for the company. As such, the filing itself provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this report.

Keywords

Zymeworks, ZYME, Kenneth Galbraith, Form 4, SEC filing, insider trading, RSU vesting, stock sale, executive compensation, beneficial ownership, Rule 10b5-1